VT-1598 tosylate structure
|
Common Name | VT-1598 tosylate | ||
---|---|---|---|---|
CAS Number | 2089321-00-4 | Molecular Weight | 756.72 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C38H28F4N6O5S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of VT-1598 tosylateVT-1598 tosylate is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 tosylate shows anti-fungal activity against C. auris[1][2]. |
Name | VT-1598 tosylate |
---|
Description | VT-1598 tosylate is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 tosylate shows anti-fungal activity against C. auris[1][2]. |
---|---|
Related Catalog | |
Target |
CYP51[1] |
In Vitro | VT-1598 甲苯磺酸盐 (0.015-8 μg/mL; 24 h) 对临床念珠菌 (C. auris) 具有体外抑制活性[1]。 VT-1598 甲苯磺酸盐 (0.03125-0.125 μg/mL; 24 h) 对临床念珠菌 (C. auris) 的体外生长有显著抑制作用[2]。 |
In Vivo | VT-1598 甲苯磺酸盐 (口服灌胃; 5, 15, and 50 mg/kg; 每天一次; 7 天) 处理小鼠,使其呈剂量依赖性的生存优势,VT-1598 还剂量依赖性降低小鼠体内的真菌负荷量[1]。 VT-1598 甲苯磺酸盐 (口服灌胃; 3.2, 8, and 20 mg/kg; 每天一次; 4 天) 在感染白色念珠菌 (C. albicans) 的 Act1 缺陷小鼠的血浆和舌中大量存在[2]。 Animal Model: Mice model of invasive candidiasis[1] Dosage: 5 mg/kg, 15 mg/kg, and 50 mg/kg Administration: Oral gavage; once daily; 7 days Result: Observed median survival in the VT-1598 15 mg/kg and 50 mg/kg groups (15 days and >21 days, respectively) longer than the control group. Observed kidney fungal burden in mice treated with 15 mg/kg and 50 mg/kg doses (mean log10 CFU/g, 5.40 and 3.67, respectively) lower than the vehicle control group. Showed mean trough concentrations 1.55 μg/mL after 7 days of therapy in the 5 mg/kg group, 6.78 μg/mL in the 15 mg/kg group, and 14.2 μg/mL in the 50 mg/kg group. Animal Model: Act1-deficient mice infected with C. albicans[2] Dosage: 3.2, 8, and 20 mg/kg Administration: Oral gavage; once daily; 4 days Result: Resulted in high concentrations in the plasma and tongues of Candida-infected mice. |
References |
Molecular Formula | C38H28F4N6O5S |
---|---|
Molecular Weight | 756.72 |